617706-18-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-bromo-2-fluorophenyl)-2,2,2-trifluoroethanone serves as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new medications. Its unique chemical structure allows for the creation of a variety of drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 1-(4-bromo-2-fluorophenyl)-2,2,2-trifluoroethanone is employed as an intermediate for the synthesis of agrochemicals. It plays a role in the production of pesticides and other agricultural chemicals that are essential for crop protection and enhancement of agricultural yields.
It is imperative to handle 1-(4-bromo-2-fluorophenyl)-2,2,2-trifluoroethanone with care due to its potential health risks. Adherence to safety guidelines is essential to mitigate any risks associated with its use in research, development, and manufacturing processes.

Upstream product

• 632324-41-5 1-bromo-3-fluoro-2-(trimethylsilyl)benzene 
• 1033805-88-7 1-(4-bromo-2-fluorophenyl)-2,2,2-trifluoroethanol 
• 1073-06-9 3-fluorobromobenzene 

Downstream Products

• 1184850-48-3 (E)-1-(4-bromo-2-fluoro-phenyl)-2,2,2-trifluoro-ethanone oxime 
• 1346689-93-7 2-(4-bromo-2-fluorophenyl)-1,1,1-trifluoropropan-2-ol 
• 1418297-00-3 3-{(Z)-1-fluoro-2-[3-fluoro-4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]vinyl}-5-methyl-1H-pyrazole 
• 1346689-94-8 2-(4-bromo-2-fluorophenyl)-1,1,1-trifluoropropan-2-yl methanesulphonate 
• 1346689-95-9 4-bromo-2-fluoro-1-(1,1,1-trifluoro-2-methylpropan-2-yl)benzene 
• 1418297-01-4 3-fluoro-4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzaldehyde 
• 1418296-19-1 (1-{3-[(3-{(Z)-1-fluoro-2-[3-fluoro-4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]vinyl}-5-methyl-1H-pyrazol-1-yl)methyl]phenyl}cyclopropyl)methanol 
• 1418297-02-5 3-{(Z)-1-fluoro-2-[3-fluoro-4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]vinyl}-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole 
• 1374258-63-5 6-bromo-3-(trifluoromethyl)-1H-indazole 

Relevant academic research and scientific papers

AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS

The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

3-(Fluorovinyl)pyrazoles and their use

The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

Highly efficient synthesis of aryl and heteroaryl trifluoromethyl ketones via o-iodobenzoic acid (IBX)

A two-step process for the synthesis of aryl and heteroaryl trifluoromethyl ketones from the corresponding aldehydes is described. Trifluoromethyl alcohols were prepared from aryl and heteroaryl aldehydes in excellent yields using catalytic amount of K2CO3. The trifluoromethyl alcohols were then oxidized conveniently and efficiently by o-iodoxybenzoic acid (IBX) under mild conditions to get the desired functionalized aryl and heteroaryl trifluoromethyl ketones.

N1/N2-Lactam Acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal

ETHYLENE DIAMINE MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain ethylene diamine compounds of Formula (I) are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Synthesis of substituted 3-trifluoromethylbenzo[b]thiophenes

A straightforward method for the synthesis of 5/6-substituted 3-trifluoromethylbenzo[b]thiophenes and their precursor o-fluorinated trifluoro acetophenones is reported.